Nanotechnology-based systems for the treatment and prevention of HIV/AIDS

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 458-477

  das Neves, José ^a   Amiji, Mansoor M ^b   Bahia, Maria Fernanda ^a   Sarmento, Bruno ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Central nervous system; Drug carriers; Drug targeting; HIV reservoir sites; Lymphatic system; Macrophages; Microbicides; Vaccines

Indexed keywords

ANTIRETROVIRALS; CENTRAL NERVOUS SYSTEMS; DRUG CARRIER; DRUG-TARGETING; LYMPHATIC SYSTEM; LYMPHATIC SYSTEMS; MICROBICIDES; RESERVOIR SITES;

DISEASES; DRUG DELIVERY; DRUG DOSAGE; MACROPHAGES; VACCINES; VIRUSES;

NANOSYSTEMS;

ABACAVIR; ALBUMIN; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LIPOSOME; LOPINAVIR; MICROBICIDE; NANOCARRIER; NANOPARTICLE; NELFINAVIR; NEVIRAPINE; NONOXINOL 9; POLYMETHACRYLIC ACID DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL TYPE; CLINICAL TRIAL; CONDOM; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INFECTION CONTROL; LYMPHOID ORGAN; NANOTECHNOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; TARGET CELL; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

AIDS VACCINES; ANTI-HIV AGENTS; DISEASE RESERVOIRS; HIV; HIV INFECTIONS; HUMANS; NANOTECHNOLOGY;

EID: 76849095367     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.017     Document Type: Review

References (223)

1. UNAIDS. Report on the Global AIDS Epidemic (2008), United Nations, Geneva, Switzerland
2. Department of Economic and Social Affairs/Population Division, United Nations. The Impact of AIDS (2004), United Nations Publications, New York, NY
3. Stover J., and Bollinger L. The economic impact of AIDS. In: Wusu O. (Ed). Politics and Economics of Africa vol. 6 (2006), Nova Science Publishers, New York, NY 1-15
4. Simon V., Ho D.D., and Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368 (2006) 489-504
5. Von Briesen H., Ramge P., and Kreuter J. Controlled release of antiretroviral drugs. AIDS Rev. 2 (2000) 31-38
6. Ojewole E., Mackraj I., Naidoo P., and Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur. J. Pharm. Biopharm. 70 (2008) 697-710
7. Vyas T.K., Shah L., and Amiji M.M. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv. 3 (2006) 613-628
8. Shahiwala A., and Amiji M.M. Nanotechnology-based delivery systems in HIV/AIDS therapy. Future HIV Ther. 1 (2007) 49-59
9. Lanao J.M., Briones E., and Colino C.I. Recent advances in delivery systems for anti-HIV1 therapy. J. Drug Target. 15 (2007) 21-36
10. Govender T., Ojewole E., Naidoo P., and Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 15 (2008) 493-501
11. Chowdhury D.F. Pharmaceutical nanosystems: manufacture, characterization, and safety. In: Gad S.C. (Ed). Pharmaceutical Manufacturing Handbook: Production and Processes (2008), Wiley, Hoboken, NJ 1289-1325
12. Torchilin V. Nanoparticulates as Drug Carriers (2006), Imperial College Press, London
13. Torchilin V. Multifunctional Pharmaceutical Nanocarriers (2008), Springer, New York, NY
14. Levy J.A. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 23 (2009) 147-160
15. Fauci A.S. Pathogenesis of HIV disease: opportunities for new prevention interventions. Clin. Infect. Dis. 45 (2007) S206-S212
16. Levy J.A. HIV and the pathogenesis of AIDS. 3rd ed. (2007), American Society of Microbiology Press, Washington, DC
17. Thomson M.M., and Najera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev. 7 (2005) 210-224
18. de Silva T.I., Cotten M., and Rowland-Jones S.L. HIV-2: the forgotten AIDS virus. Trends Microbiol. 16 (2008) 588-595
19. Cohen M.S., Hellmann N., Levy J.A., DeCock K., and Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J. Clin. Invest. 118 (2008) 1244-1254
20. Haase A.T. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu. Rev. Immunol. 17 (1999) 625-656
21. Connor R.I., Sheridan K.E., Ceradini D., Choe S., and Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185 (1997) 621-628
22. McCutchan F.E. Global epidemiology of HIV. J. Med. Virol. 78 (2006) S7-S12
23. Miller C.J., and Shattock R.J. Target cells in vaginal HIV transmission. Microbes Infect. 5 (2003) 59-67
24. Miller C.J., Alexander N.J., Vogel P., Anderson J., and Marx P.A. Mechanism of genital transmission of SIV: a hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. J. Med. Primatol. 21 (1992) 64-68
25. Royce R.A., Sena A., Cates Jr. W., and Cohen M.S. Sexual transmission of HIV. N. Engl. J. Med. 336 (1997) 1072-1078
26. Collins K.B., Patterson B.K., Naus G.J., Landers D.V., and Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6 (2000) 475-479
27. Hladik F., and McElrath M.J. Setting the stage: host invasion by HIV. Nat. Rev., Immunol. 8 (2008) 447-457
28. Geijtenbeek T.B.H., Kwon D.S., Torensma R., Van Vliet S.J., Van Duijnhoven G.C.F., Middel J., Cornelissen I.L.M.H.A., Nottet H.S.L.M., KewalRamani V.N., Littman D.R., Figdor C.G., and Van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 (2000) 587-597
29. Poonia B., Wang X., and Veazey R.S. Distribution of simian immunodeficiency virus target cells in vaginal tissues of normal rhesus macaques: implications for virus transmission. J. Reprod. Immunol. 72 (2006) 74-84
30. Wilkinson J., and Cunningham A.L. Mucosal transmission of HIV-1: first stop dendritic cells. Curr. Drug Targets 7 (2006) 1563-1569
31. Soto-Ramirez L.E., Renjifo B., McLane M.F., Marlink R., O'Hara C., Sutthent R., Wasi C., Vithayasai P., Vithayasai V., Apichartpiyakul C., Auewarakul P., Peña Cruz V., Chui D.S., Osathanondh R., Mayer K., Lee T.H., and Essex M. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 271 (1996) 1291-1293
32. Galvin S.R., and Cohen M.S. The role of sexually transmitted diseases in HIV transmission. Nat. Rev. Microbiol. 2 (2004) 33-42
33. Kilmarx P.H., Limpakarnjanarat K., Supawitkul S., Korattana S., Young N.L., Parekh B.S., Respess R.A., Mastro T.D., and St Louis M.E. Mucosal disruption due to use of a widely-distributed commercial vaginal product: potential to facilitate HIV transmission. AIDS 12 (1998) 767-773
34. Lackner A.A., and Veazey R.S. Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu. Rev. Med. 58 (2007) 461-476
35. McCoombe S.G., and Short R.V. Potential HIV-1 target cells in the human penis. AIDS 20 (2006) 1491-1495
36. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., Boden D., Racz P., and Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200 (2004) 761-770
37. Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., and Dandekar S. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77 (2003) 11708-11717
38. Brenchley J.M., and Douek D.C. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1 (2008) 23-30
39. Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., Meehan M.O., Lutalo T., and Gray R.H. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342 (2000) 921-929
40. Pilcher C.D., Eron Jr. J.J., Galvin S., Gay C., and Cohen M.S. Acute HIV revisited: new opportunities for treatment and prevention. J. Clin. Invest. 113 (2004) 937-945
41. Blankson J.N., Persaud D., and Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53 (2002) 557-593
42. Schrager L.K., and D'Souza M.P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280 (1998) 67-71
43. Venzke S., and Keppler O.T. Role of macrophages in HIV infection and persistence. Expert Rev. Clin. Immunol. 2 (2006) 613-626
44. Carter C.A., and Ehrlich L.S. Cell biology of HIV-1 infection of macrophages. Annu. Rev. Microbiol. 62 (2008) 425-443
45. González-Scarano F., and Martín-García J. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5 (2005) 69-81
46. Barbaro G., Scozzafava A., Mastrolorenzo A., and Supuran C.T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 11 (2005) 1805-1843
47. Babiker A., Darby S., De Angelis D., Ewart D., Porter K., Beral V., Darbyshire J., Day N., and Gill N. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 355 (2000) 1131-1137
48. Gill C.J., Griffith J.L., Jacobson D., Skinner S., Gorbach S.L., and Wilson I.B. Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life. J. Acquir. Immune Defic. Syndr. 30 (2002) 485-492
49. Porter K., Babiker A., Bhaskaran K., Darbyshire J., Pezzotti P., and Walker A.S. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362 (2003) 1267-1274
50. Hammer S.M., Eron Jr. J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., Cahn P., Fischl M.A., Gatell J.M., Hirsch M.S., Jacobsen D.M., Montaner J.S., Richman D.D., Yeni P.G., and Volberding P.A. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300 2008 (2008) 555-570
51. Blum M.R., Liao S.H., Good S.S., and de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85 (1988) 189-194
52. Barry M., Mulcahy F., Merry C., Gibbons S., and Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokinet. 36 (1999) 289-304
53. Hartman N.R., Yarchoan R., Pluda J.M., Thomas R.V., Marczyk K.S., Broder S., and Johns D.G. Pharmacokinetics of 2′, 3′-dideoxyadenosine and 2′, 3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther. 47 (1990) 647-654
54. Shelton M.J., O'Donnell A.M., and Morse G.D. Didanosine. Ann. Pharmacother. 26 5 (1992) 660-670
55. Chappuy H., Treluyer J.M., Jullien V., Dimet J., Rey E., Fouche M., Firtion G., Pons G., and Mandelbrot L. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48 (2004) 4332-4336
56. Yarchoan R., Perno C.F., Thomas R.V., Klecker R.W., Allain J.P., Wills R.J., McAtee N., Fischl M.A., Dubinsky R., McNeely M.C., Mitsuya H., Pluda J.M., Lawley T.J., Leuther M., Safai B., Collins J.M., Myers C.E., and Broder S. Phase I studies of 2′, 3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1 (1988) 76-81
57. Haworth S.J., Christofalo B., Anderson R.D., and Dunkle L.M. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17 (1998) 235-238
58. Lea A.P., and Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 51 (1996) 846-864
59. Dumond J.B., Yeh R.F., Patterson K.B., Corbett A.H., Jung B.H., Rezk N.L., Bridges A.S., Stewart P.W., Cohen M.S., and Kashuba A.D. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21 (2007) 1899-1907
60. van Leeuwen R., Katlama C., Kitchen V., Boucher C.A., Tubiana R., McBride M., Ingrand D., Weber J., Hill A., McDade H., et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171 (1995) 1166-1171
61. Mandelbrot L., Peytavin G., Firtion G., and Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am. J. Obstet. Gynecol. 184 (2001) 153-158
62. Bennetto-Hood C., Bryson Y.J., Stek A., King J.R., Mirochnick M., and Acosta E.P. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clin. Trials 10 (2009) 41-47
63. Foster R.H., and Faulds D. Abacavir. Drugs 55 (1998) 729-736
64. 50 in cerebrospinal fluid: CHARTER findings. 16th Conference on Retrovirus and Opportunistic Infections, Montréal, Canada (2009)
65. Anthonypillai C., Gibbs J.E., and Thomas S.A. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res. 3 (2006) 1
66. Taylor S., van Heeswijk R.P., Hoetelmans R.M., Workman J., Drake S.M., White D.J., and Pillay D. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 14 (2000) 1979-1984
67. Smith P.F., DiCenzo R., and Morse G.D. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40 (2001) 893-905
68. Kwara A., Delong A., Rezk N., Hogan J., Burtwell H., Chapman S., Moreira C.C., Kurpewski J., Ingersoll J., Caliendo A.M., Kashuba A., and Cu-Uvin S. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin. Infect. Dis. 46 (2008) 719-725
69. Deeks E.D., and Keating G.M. Etravirine. Drugs 68 (2008) 2357-2372
70. Vella S., and Floridia M. Saquinavir: clinical pharmacology and efficacy. Clin. Pharmacokinet. 34 (1998) 189-201
71. Kravcik S., Gallicano K., Roth V., Cassol S., Hawley-Foss N., Badley A., and Cameron D.W. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J. Acquir. Immune Defic. Syndr. 21 (1999) 371-375
72. Gingelmaier A., Kurowski M., Kastner R., Eberle J., Mylonas I., Belohradsky B.H., Friese K., and Grubert T.A. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 20 (2006) 1737-1743
73. Solas C., Lafeuillade A., Halfon P., Chadapaud S., Hittinger G., and Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47 (2003) 238-243
74. Khoo S.H., Hoggard P.G., Williams I., Meaden E.R., Newton P., Wilkins E.G., Smith A., Tjia J.F., Lloyd J., Jones K., Beeching N., Carey P., Peters B., and Back D.J. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob. Agents Chemother. 46 (2002) 3228-3235
75. Chappuy H., Treluyer J.M., Rey E., Dimet J., Fouche M., Firtion G., Pons G., and Mandelbrot L. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am. J. Obstet. Gynecol. 191 (2004) 558-562
76. R.F. Yeh, N.L. Rezk, A.D. Kashuba, J.B. Dumond, H.L. Tappouni, H.C. Tien, Y.C. Chen, M. Vourvahis, A.L. Horton, S.A. Fiscus, K.B. Patterson, Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in HIV-1 infected women. Antimicrob. Agents Chemother. 53 (2009) 2367-2374.
77. Aweeka F., Jayewardene A., Staprans S., Bellibas S.E., Kearney B., Lizak P., Novakovic-Agopian T., and Price R.W. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20 (1999) 39-43
78. Kumar G.N., Jayanti V.K., Johnson M.K., Uchic J., Thomas S., Lee R.D., Grabowski B.A., Sham H.L., Kempf D.J., Denissen J.F., Marsh K.C., Sun E., and Roberts S.A. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res. 21 (2004) 1622-1630
79. Best B.M., Letendre S.L., Brigid E., Clifford D.B., Collier A.C., Gelman B.B., McArthur J.C., McCutchan J.A., Simpson D.M., Ellis R., Capparelli E.V., and Grant I. Low atazanavir concentrations in cerebrospinal fluid. AIDS 23 (2009) 83-87
80. Pereira A., Eron J., Dunn J., Gerber J., Tidwell R., Kenney K., Fiscus S., Sommadossi J.-P., Tung R., Gulick R., and Murphy R. Analysis of amprenavir (APV)/3TC/ZDV in blood and seminal plasma: penetration of APV into the male genital tract. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco (2000)
81. Croom K.F., and Keam S.J. Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 65 (2005) 1669-1677
82. Yilmaz A., Izadkhashti A., Price R.W., Mallon P.W., De Meulder M., Timmerman P., and Gisslen M. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res. Hum. Retrovir. 25 (2009) 457-461
83. Price R.W., Parham R., Kroll J.L., Wring S.A., Baker B., Sailstad J., Hoh R., Liegler T., Spudich S., Kuritzkes D.R., and Deeks S.G. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir. Ther. 13 (2008) 369-374
84. Walker D.K., Bowers S.J., Mitchell R.J., Potchoiba M.J., Schroeder C.M., and Small H.F. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 38 (2008) 1330-1339
85. Cocohoba J., and Dong B.J. Raltegravir: the first HIV integrase inhibitor. Clin. Ther. 30 (2008) 1747-1765
86. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6 (2007) 1001-1018
87. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16 (2008) 138-145
88. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
89. Aungst B.J. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 39 (1999) 105-116
90. Kukhanova M., Krayevsky A., Prusoff W., and Cheng Y.C. Design of anti-HIV compounds: from nucleoside to nucleoside 5′-triphosphate analogs. Problems and perspectives. Curr. Pharm. Des. 6 (2000) 585-598
91. von Kleist M., and Huisinga W. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine. Eur. J. Pharm. Sci. 36 (2009) 532-543
92. Tymchuk C.N., and Currier J.S. The safety of antiretroviral drugs. Expert Opin. Drug Saf. 7 (2008) 1-4
93. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2 (2003) 624-634
94. No authors. Drugs for HIV infection. Treat. Guidel. Med. Lett. (2009) 11-22
95. Danel C., Moh R., Minga A., Anzian A., Ba-Gomis O., Kanga C., Nzunetu G., Gabillard D., Rouet F., Sorho S., Chaix M.L., Eholie S., Menan H., Sauvageot D., Bissagnene E., Salamon R., and Anglaret X. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367 (2006) 1981-1989
96. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., Babiker A., Burman W., Clumeck N., Cohen C.J., Cohn D., Cooper D., Darbyshire J., Emery S., Fatkenheuer G., Gazzard B., Grund B., Hoy J., Klingman K., Losso M., Markowitz N., Neuhaus J., Phillips A., and Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355 (2006) 2283-2296
97. Ojikutu B., Jack C., and Ramjee G. Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles. J. Infect. Dis. 196 (2007) S523-S527
98. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 455 (2008) 613-619
99. Lederman M.M., Offord R.E., and Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6 (2006) 371-382
100. Li S.D., and Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5 (2008) 496-504
101. Hillaireau H., Le Doan T., Besnard M., Chacun H., Janin J., and Couvreur P. Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules. Int. J. Pharm. 324 (2006) 37-42
102. Hillaireau H., Le Doan T., Chacun H., Janin J., and Couvreur P. Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. Int. J. Pharm. 331 (2007) 148-152
103. De Jaeghere F., Allémann E., Kubel F., Galli B., Cozens R., Doelker E., and Gurny R. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J. Control. Release 68 (2000) 291-298
104. Boudad H., Legrand P., Appel M., Coconnier M., and Ponchel G. Formulation and cytotoxicity of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on Caco-2 cells monolayers intended for oral administration of saquinavir. STP Pharma. Sci. 11 (2001) 369-375
105. Leroux J.C., Cozens R.M., Roesel J.L., Galli B., Doelker E., and Gurny R. pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs. Pharm. Res. 13 (1996) 485-487
106. Langer R. Drug delivery and targeting. Nature 392 6679 Suppl. (1998) 5-10
107. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
108. Choi S.U., Bui T., and Ho R.J. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J. Pharm. Sci. 97 (2008) 931-943
109. Phillips N.C., and Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79 (1992) 1137-1143
110. Kohli E., Han H.Y., Zeman A.D., and Vinogradov S.V. Formulations of biodegradable Nanogel carriers with 5′-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. J. Control. Release 121 (2007) 19-27
111. Heiati H., Tawashi R., and Phillips N.C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization. J. Microencapsul. 15 (1998) 173-184
112. Kuo Y.C. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 290 (2005) 161-172
113. Garg M., Dutta T., and Jain N.K. Stability study of stavudine-loaded O-palmitoyl-anchored carbohydrate-coated liposomes. AAPS PharmSciTech 8 (2007) Article 38
114. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55 (2003) 329-347
115. Dinauer N., Lochmann D., Demirhan I., Bouazzaoui A., Zimmer A., Chandra A., Kreuter J., and von Briesen H. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J. Control. Release 96 (2004) 497-507
116. Schäfer V., von Briesen H., Andreesen R., Steffan A.M., Royer C., Troster S., Kreuter J., and Rubsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9 (1992) 541-546
117. Bender A., Schäfer V., Steffan A.M., Royer C., Kreuter J., Rubsamen-Waigmann H., and von Briesen H. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res. Virol. 145 (1994) 215-220
118. Bender A.R., von Briesen H., Kreuter J., Duncan I.B., and Rubsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40 (1996) 1467-1471
119. Shah L.K., and Amiji M.M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23 (2006) 2638-2645
120. Mainardes R.M., Gremião M.P., Brunetti I.L., da Fonseca L.M., and Khalil N.M. Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J. Pharm. Sci. 98 (2009) 257-267
121. Dou H., Morehead J., Destache C.J., Kingsley J.D., Shlyakhtenko L., Zhou Y., Chaubal M., Werling J., Kipp J., Rabinow B.E., and Gendelman H.E. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358 (2007) 148-158
122. Vinogradov S.V., Kohli E., and Zeman A.D. Cross-linked polymeric nanogel formulations of 5′-triphosphates of nucleoside analogues: role of the cellular membrane in drug release. Mol. Pharm. 2 (2005) 449-461
123. Hillaireau H., Le Doan T., Appel M., and Couvreur P. Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J. Control. Release 116 (2006) 346-352
124. Flasher D., Konopka K., Chamow S.M., Dazin P., Ashkenazi A., Pretzer E., and Düzgüneş N. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim. Biophys. Acta 1194 (1994) 185-196
125. Couvreur P., Stella B., Reddy L.H., Hillaireau H., Dubernet C., Desmaele D., Lepetre-Mouelhi S., Rocco F., Dereuddre-Bosquet N., Clayette P., Rosilio V., Marsaud V., Renoir J.M., and Cattel L. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 6 (2006) 2544-2548
126. Bekkara-Aounallah F., Gref R., Othman M., Reddy L.H., Pili B., Allain V., Bourgaux C., Hillaireau H., Lepêtre-Mouelhi S., Desmaële D., Nicolas J., Chafi N., and Couvreur P. Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues. Adv. Funct. Mater. 18 (2008) 3715-3725
127. Ganta S., Devalapally H., Shahiwala A., and Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 126 (2008) 187-204
128. Düzgüneş N., Simões S., Slepushkin V., Pretzer E., Rossi J.J., De Clercq E., Antao V.P., Collins M.L., and Pedroso de Lima M.C. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acids 20 (2001) 515-523
129. Ece Gamsiz D., Shah L.K., Devalapally H., Amiji M.M., and Carrier R.L. A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells. Biotechnol. Bioeng. 101 (2008) 1072-1082
130. Löbenberg R., and Kreuter J. Macrophage targeting of azidothymidine: a promising strategy for AIDS therapy. AIDS Res. Hum. Retroviruses 12 (1996) 1709-1715
131. Löbenberg R., Araujo L., von Briesen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 (1998) 21-30
132. 14C-labelled AZT bound to nanoparticles in rats determined by radioluminography. J. Drug Target. 5 (1998) 171-179
133. Löbenberg R., Araujo L., and Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44 (1997) 127-132
134. Dembri A., Montisci M.J., Gantier J.C., Chacun H., and Ponchel G. Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm. Res. 18 (2001) 467-473
135. Jin Y., Ai P., Xin R., and Chen D. Morphological transformation of self-assembled nanostructures prepared from cholesteryl acyl didanosine and the optimal formulation of nanoparticulate systems: effects of solvents, acyl chain length and poloxamer 188. J. Colloid Interface Sci. 326 (2008) 275-282
136. Jin Y., Xin R., Ai P., and Chen D. Self-assembled drug delivery systems 2. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation. Int. J. Pharm. 350 (2008) 330-337
137. Jin Y., Ai P., Xin R., Tian Y., Dong J., Chen D., and Wang W. Self-assembled drug delivery systems: part 3. In vitro/in vivo studies of the self-assembled nanoparticulates of cholesteryl acyl didanosine. Int. J. Pharm. 368 (2009) 207-214
138. 287-infected macaques. J. Acquir. Immune Defic. Syndr. 34 (2003) 387-397
139. Kinman L., Bui T., Larsen K., Tsai C.C., Anderson D., Morton W.R., Hu S.L., and Ho R.J. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J. Acquir. Immune Defic. Syndr. 42 (2006) 155-161
140. Snedecor S.J., Sullivan S.M., and Ho R.J. Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir. Pharm. Res. 23 (2006) 1750-1755
141. Garg M., Dutta T., and Jain N.K. Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm. 67 (2007) 76-85
142. Garg M., Garg B.R., Jain S., Mishra P., Sharma R.K., Mishra A.K., Dutta T., and Jain N.K. Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes. Eur. J. Pharm. Sci. 33 (2008) 271-281
143. Gagné J.F., Désormeaux A., Perron S., Tremblay M.J., and Bergeron M.G. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim. Biophys. Acta 1558 (2002) 198-210
144. Dou H., Destache C.J., Morehead J.R., Mosley R.L., Boska M.D., Kingsley J., Gorantla S., Poluektova L., Nelson J.A., Chaubal M., Werling J., Kipp J., Rabinow B.E., and Gendelman H.E. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108 8 (2006) 2827-2835
145. Gorantla S., Dou H., Boska M., Destache C.J., Nelson J., Poluektova L., Rabinow B.E., Gendelman H.E., and Mosley R.L. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J. Leukoc. Biol. 80 5 (2006) 1165-1174
146. Jain S., Tiwary A.K., and Jain N.K. Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. Curr. Drug Deliv. 3 2 (2006) 157-166
147. Jain S., Tiwary A.K., and Jain N.K. PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine. Curr. Drug Deliv. 5 4 (2008) 275-281
148. Jain S., Tiwary A.K., Sapra B., and Jain N.K. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech 8 4 (2007) E111
149. Garg M., Asthana A., Agashe H.B., Agrawal G.P., and Jain N.K. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 58 (2006) 605-616
150. Désormeaux A., Harvie P., Perron S., Makabi-Panzu B., Beauchamp D., Tremblay M., Poulin L., and Bergeron M.G. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2′, 3′-dideoxyinosine. AIDS 8 (1994) 1545-1553
151. P. Harvie, A. Désormeaux, N. Gagné, M. Tremblay, L. Poulin, D. Beauchamp, M.G. Bergeron, Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 9 (7) (1995) 701-707.
152. Oussoren C., Magnani M., Fraternale A., Casabianca A., Chiarantini L., Ingebrigsten R., Underberg W.J., and Storm G. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate. Int. J. Pharm. 180 (1999) 261-270
153. Heiati H., Tawashi R., and Phillips N.C. Solid lipid nanoparticles as drug carriers. II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate in mice. Int. J. Pharm. 174 (1998) 71-80
154. Kaur C.D., Nahar M., and Jain N.K. Lymphatic targeting of zidovudine using surface-engineered liposomes. J. Drug Target. 16 (2008) 798-805
155. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004) 29-45
156. Tiwari S.B., and Amiji M.M. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv. 3 (2006) 219-232
157. Sawchuk R.J., and Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv. Drug Deliv.
158. Kim S., Scheerer S., Geyer M.A., and Howell S.B. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J. Infect. Dis. 162 (1990) 750-752
159. Kuo Y.C., and Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 327 (2006) 160-169
160. Kuo Y.C., and Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 340 (2007) 143-152
161. Kuo Y.C., and Chen H.H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365 (2009) 206-213
162. Vyas T.K., Shahiwala A., and Amiji M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 347 (2008) 93-101
163. Mishra V., Mahor S., Rawat A., Gupta P.N., Dubey P., Khatri K., and Vyas S.P. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target. 14 (2006) 45-53
164. Rao K.S., Reddy M.K., Horning J.L., and Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29 33 (2008) 4429-4438
165. Kaur A., Jain S., and Tiwary A.K. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 58 (2008) 61-74
166. Dou H., Grotepas C.B., McMillan J.M., Destache C.J., Chaubal M., Werling J., Kipp J., Rabinow B., and Gendelman H.E. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183 (2009) 661-669
167. Balzarini J., and Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 369 (2007) 787-797
168. Moscicki A.B. Vaginal microbicides: where are we and where are we going?. J. Infect. Chemother. 14 (2008) 337-341
169. van de Wijgert J.H., and Shattock R.J. Vaginal microbicides: moving ahead after an unexpected setback. AIDS 21 18 (2007) 2369-2376
170. das Neves J., Santos B., Cunha T., Teixeira B., Rocha P., and Dias G. Vaginal microbicides: the importance of effective distribution, retention and coating of the mucosa. AIDS 22 (2008) 908-909
171. das Neves J., and Bahia M.F. Gels as vaginal drug delivery systems. Int. J. Pharm. 318 (2006) 1-14
172. Rohan L.C., and Sassi A.B. Vaginal drug delivery systems for HIV prevention. AAPS J. 11 (2009) 78-87
173. Hayakawa T., Kawamura M., Okamoto M., Baba M., Niikawa T., Takehara S., Serizawa T., and Akashi M. Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: potential approach towards prevention of viral transmission. J. Med. Virol. 56 (1998) 327-331
174. Wang X., Akagi T., Akashi M., and Baba M. Development of core-corona type polymeric nanoparticles as an anti-HIV-1 vaccine. Mini-Rev. Org. Chem. 4 1 (2007) 51-59
175. de la Fuente J.M., and Penadés S. Understanding carbohydrate-carbohydrate interactions by means of glyconanotechnology. Glycoconj. J. 21 (2004) 149-163
176. Martínez-Ávila O., Clavel C., Penadés S., Stefanidou M., Hayes M., Shattock R., Hijazi K., and Kelly C. Gold manno-nanoparticles as potential microbicides against HIV infection. TNT2007 - Trends in NanoTechnology, San Sebastian, Spain (2007)
177. Stefanidou M., Martinez O., Hayes M., Clavel C., Champion C., Penades S., and Shattock R. Evaluation of gold manno-nanoparticles in a model for DC-SIGN binding and dissemination of HIV-1. Microbicides 2006 Conference, Cape Town, South Africa (2006)
178. Ham A.S., Cost M.R., Sassi A.B., Dezzutti C.S., and Rohan L.C. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 26 (2009) 502-511
179. Lederman M.M., Veazey R.S., Offord R., Mosier D.E., Dufour J., Mefford M., Piatak Jr. M., Lifson J.D., Salkowitz J.R., Rodriguez B., Blauvelt A., and Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306 5695 (2004) 485-487
180. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., and Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1482-1487
181. Cu Y., and Saltzman W.M. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharm. 6 (2009) 173-181
182. K.A. Woodrow, Y. Cu, C.J. Booth, J.K. Saucier-Sawyer, M.J. Wood, W.M. Saltzman, Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 8 (2009) 526-533.
183. Kish-Catalone T.M., Lu W., Gallo R.C., and DeVico A.L. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5. Antimicrob. Agents Chemother. 50 (2006) 1497-1509
184. Kish-Catalone T., Pal R., Parrish J., Rose N., Hocker L., Hudacik L., Reitz M., Gallo R., and Devico A. Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model. AIDS Res. Hum. Retroviruses 23 (2007) 33-42
185. Shahiwala A., Vyas T.K., and Amiji M.M. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat. Drug Deliv. Formul. 1 (2007) 1-9
186. Peek L.J., Middaugh C.R., and Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60 (2008) 915-928
187. Locher C.P., Putnam D., Langer R., Witt S.A., Ashlock B.M., and Levy J.A. Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation. Immunol. Lett. 90 (2003) 67-70
188. Boyle J., Eastman D., Millar C., Camuglia S., Cox J., Pearse M., Good J., and Drane D. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 25 (2007) 2541-2544
189. Putkonen P., Bjorling E., Akerblom L., Thorstensson R., Lovgren K., Benthin L., Chiodi F., Morein B., Biberfeld G., Norrby E., and Wigzell H. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J. Acquir. Immune Defic. Syndr. 7 (1994) 551-559
190. Ishii N., Fukushima J., Kaneko T., Okada E., Tani K., Tanaka S.I., Hamajima K., Xin K.Q., Kawamoto S., Koff W., Nishioka K., Yasuda T., and Okuda K. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 13 (1997) 1421-1428
191. Okada E., Sasaki S., Ishii N., Aoki I., Yasuda T., Nishioka K., Fukushima J., Miyazaki J., Wahren B., and Okuda K. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159 (1997) 3638-3647
192. Xin K.Q., Hamajima K., Sasaki S., Honsho A., Tsuji T., Ishii N., Cao X.R., Lu Y., Fukushima J., Shapshak P., Kawamoto S., and Okuda K. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology 94 (1998) 438-444
193. Toda S., Ishii N., Okada E., Kusakabe K.I., Arai H., Hamajima K., Gorai I., Nishioka K., and Okuda K. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 92 (1997) 111-117
194. Sakaue G., Hiroi T., Nakagawa Y., Someya K., Iwatani K., Sawa Y., Takahashi H., Honda M., Kunisawa J., and Kiyono H. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. 170 (2003) 495-502
195. Cui Z., Patel J., Tuzova M., Ray P., Phillips R., Woodward J.G., Nath A., and Mumper R.J. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 22 (2004) 2631-2640
196. Vajdy M., Singh M., Kazzaz J., Soenawan E., Ugozzoli M., Zhou F., Srivastava I., Bin Q., Barnett S., Donnelly J., Luciw P., Adamson L., Montefiori D., and O'Hagan D.T. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 20 (2004) 1269-1281
197. Ataman-Önal Y., Munier S., Ganee A., Terrat C., Durand P.Y., Battail N., Martinon F., Le Grand R., Charles M.H., Delair T., and Verrier B. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control. Release 112 (2006) 175-185
198. Lamalle-Bernard D., Munier S., Compagnon C., Charles M.H., Kalyanaraman V.S., Delair T., Verrier B., and Ataman-Onal Y. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J. Control. Release 115 (2006) 57-67
199. Akagi T., Kawamura M., Ueno M., Hiraishi K., Adachi M., Serizawa T., Akashi M., and Baba M. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J. Med. Virol. 69 2 (2003) 163-172
200. Miyake A., Akagi T., Enose Y., Ueno M., Kawamura M., Horiuchi R., Hiraishi K., Adachi M., Serizawa T., Narayan O., Akashi M., Baba M., and Hayami M. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J. Med. Virol. 73 (2004) 368-377
201. Akagi T., Ueno M., Hiraishi K., Baba M., and Akashi M. AIDS vaccine: intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres. J. Control. Release 109 (2005) 49-61
202. Kawamura M., Wang X., Uto T., Sato K., Ueno M., Akagi T., Hiraishi K., Matsuyama T., Akashi M., and Baba M. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice. J. Med. Virol. 76 (2005) 7-15
203. Koopman G., Bogers W.M., van Gils M., Koornstra W., Barnett S., Morein B., Lehner T., and Heeney J.L. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J. Med. Virol. 79 (2007) 474-482
204. Guillon C., Mayol K., Terrat C., Compagnon C., Primard C., Charles M.H., Delair T., Munier S., and Verrier B. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 25 (2007) 7491-7501
205. Arias M.A., Loxley A., Fairhurst D., Eatmon C., Kim Y., Wegmann F., Mitchnick M., and Shattock R. HIV-gp140 antigen-adsorbed wax nanoparticles induce strong in vivo systemic and mucosal humoral immune responses. AIDS Vaccine 2008 Conference, Cape Town, South Africa (2008)
206. Kahn J.O., Sinangil F., Baenziger J., Murcar N., Wynne D., Coleman R.L., Steimer K.S., Dekker C.L., and Chernoff D. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170 (1994) 1288-1291
207. Toledo H., Baly A., Castro O., Resik S., Laferte J., Rolo F., Navea L., Lobaina L., Cruz O., Miguez J., Serrano T., Sierra B., Perez L., Ricardo M.E., Dubed M., Lubian A.L., Blanco M., Millan J.C., Ortega A., Iglesias E., Penton E., Martin Z., Perez J., Diaz M., and Duarte C.A. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19 (2001) 4328-4336
208. Bielinska A.U., Janczak K.W., Landers J.J., Markovitz D.M., Montefiori D.C., and Baker Jr. J.R. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retrovir. 24 (2008) 271-281
209. Kunisawa J., Nakagawa S., and Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv. Drug Deliv. Rev. 52 (2001) 177-186
210. Kawamura M., Naito T., Ueno M., Akagi T., Hiraishi K., Takai I., Makino M., Serizawa T., Sugimura K., Akashi M., and Baba M. Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice. J. Med. Virol. 66 (2002) 291-298
211. Diebold S.S., Kursa M., Wagner E., Cotten M., and Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem. 274 (1999) 19087-19094
212. Lisziewicz J., Kelly L., and Lori F. Topical DermaVir vaccine targeting dendritic cells. Curr. Drug Deliv. 3 (2006) 83-88
213. Lori F., Calarota S.A., and Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. Curr. Med. Chem. 14 (2007) 1911-1919
214. Lisziewicz J., Trocio J., Whitman L., Varga G., Xu J., Bakare N., Erbacher P., Fox C., Woodward R., Markham P., Arya S., Behr J.P., and Lori F. DermaVir: a novel topical vaccine for HIV/AIDS. J. Invest. Dermatol. 124 (2005) 160-169
215. Cristillo A.D., Lisziewicz J., He L., Lori F., Galmin L., Trocio J.N., Unangst T., Whitman L., Hudacik L., Bakare N., Whitney S., Restrepo S., Suschak J., Ferrari M.G., Chung H.K., Kalyanaraman V.S., Markham P., and Pal R. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 366 (2007) 197-211
216. Lisziewicz J., Trocio J., Xu J., Whitman L., Ryder A., Bakare N., Lewis M.G., Wagner W., Pistorio A., Arya S., and Lori F. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 19 (2005) 35-43
217. Sahoo S.K., and Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 8 (2003) 1112-1120
218. No authors. Sizing Nanotechnology's Value Chain (2004), Lux Research, New York
219. Bawarski W.E., Chidlowsky E., Bharali D.J., and Mousa S.A. Emerging nanopharmaceuticals. Nanomedicine 4 (2008) 273-282
220. Klasse P.J., Shattock R.J., and Moore J.P. Which topical microbicides for blocking HIV-1 transmission will work in the real world?. PLoS Med. 3 (2006) e351
221. Pharmaco-Economics Working Group. The Economics of Microbicide Development: a Case for Investment (2002), Rockefeller Foundation Microbicide Initiative, New York, NY
222. Wilson D.P., and Coplan P.M. Mathematical models and health economic aspects of microbicides. Curr. Opin. HIV AIDS 3 (2008) 587-592
223. Couvreur P., and Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23 (2006) 1417-1450